Target-Oriented Strategy of Ultra-Low LDL-C (<1.0 vs. 1.0-1.39 mmol/L) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment

Clinical trial NCT07615296 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07615296
Sponsor: Beijing Anzhen Hospital
Status: NOT_YET_RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Atherosclerotic Cardiovascular Disease (ASCVD)

Start date: 2027-01-01
Primary completion: 2029-12-31
Enrollment: 6000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.